Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

CD56(high) acute myeloid leukemias (AMLs) have a poor prognosis, but it has been unclear how CD56 expression is controlled and how it relates to clinical aggressiveness. We show that CD56 expression on AML cells correlates with an abnormal expression pattern of runt-related transcription factor 1 (RUNX1) isoforms. Whereas full-length p48 RUNX1 (p48) up-regulated CD56 in AML cells, 3 previously unknown shorter RUNX1 isoforms, p38a, p30, and p24, suppressed CD56 expression. Both p48 and CD56 induced nuclear translocation of nuclear factor (NF)-kappaB and increased bcl2L12 expression, and inhibition of this pathway by small inhibitory RNA-mediated p48 knock down or NF-kappaB blockade substantially increased apoptosis in CD56(+) AML cell lines. These findings indicate the potential for new therapy of CD56(high) AML by suppression of the "overactive" RUNX1/CD56/NF-kappaB signaling pathway(s).

Original publication

DOI

10.1182/blood-2007-02-074203

Type

Journal article

Journal

Blood

Publication Date

15/09/2007

Volume

110

Pages

2027 - 2033

Keywords

Acute Disease, Annexin A5, Antigens, CD56, Apoptosis, Blotting, Western, Case-Control Studies, Cell Nucleus, Core Binding Factor Alpha 2 Subunit, Cytosol, Gene Expression Regulation, Leukemic, Gene Library, Genes, Dominant, Humans, Immunoenzyme Techniques, Leukemia, Myeloid, Luciferases, Muscle Proteins, NF-kappa B, Protein Isoforms, Protein Transport, Proto-Oncogene Proteins c-bcl-2, RNA, Small Interfering, Reverse Transcriptase Polymerase Chain Reaction, Ribonucleases, Tumor Cells, Cultured